期刊文献+

特尔康联合泼尼松治疗特发性血小板减少性紫癜(ITP)16例临床研究报告 被引量:1

下载PDF
导出
摘要 目的研究重组人白细胞介素11(特尔康)对特发性血小板减少性紫癜的治疗作用。方法选择经过传统药物治疗而血小板仍处于较低水平的16例特发性血小板减少性紫癜患者。在泼尼松1mg/(kg·d)治疗的基础上,伴随使用特尔康150μg/d,7~14d,14d后停止治疗。结果治疗后所有患者血小板数明显增加,与此同时使反复发作的特发性血小板减少性紫癜患者得到了持续缓解。结论特尔康对特发性血小板减少性紫癜有较好的治疗效果。
作者 王巍
出处 《中国现代药物应用》 2010年第16期173-174,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献3

二级参考文献15

  • 1PaulSR,SchendelP.Thecloningandbiologicalcharacterizationofrecombinanthumaninterleukin-11.IntJCellCloning,1992;10:135-143
  • 2DuXX,WilliamsDA.Interleukin11:amultifunetionalgrowthfactorderivedfromthehematopoieticmicroenvironment.Blood,1994;83:2023-2030
  • 3BrunoE,BriddellRA,CooperRJ,etal.Effectsofrecombinantinterleukin-11onhumanmegakaryocyteprogenitorcells.ExpHematol,1991;19:378-381
  • 4TeramuraM,KobayashiS,HoshinoS,etal.Interleukin11enhanceshumanmegakaryocytopoiesisinvitro.Blood,1992;79:327-331
  • 5NebenTY,LoebelenzJ,HayesL,etal.Recombinanthumaninterleukin-11stimulatesmegakaryocytopoiesisandincreasesperipheralplateletsinnormalandsplenectomizedmice.Blood,1993;81:901-908
  • 6BreeA,SchlermanF,TimonyG,etal.Pharmacokineticsandthrombopoieticeffectsofrecombinanthumaninterleukin-11(rhIL-11)innonhumanprimatesandrodents(abstr).Blood,1991;78(suppl1):132
  • 7LeonardJP,QuintoCM,KozitzaMK,etal.Recombinanthumaninterleukin-11stimulatesmultilineagehematopoieticrecoveryinmiceafteramyelosuppressiveregimenofsublethalirradiationandcarboplatin.Blood,1994;83:1499-1506
  • 8HangocG,YinT,CooperS,etal.Invivoeffectsofrecombinantinterleukin-11onmyelopoiesisinmice.Blood,1993;81:965-972
  • 9SchlermanFJ,BreeAG,KavianiMD,etal.Thrombopoieticactivityofrecombinanthumaninterleukin11(rHuIL11)innormalandmyelosuppressednonhumanprimates.StemCells,1996;14:517-532
  • 10Reynolds CH.Clinical efficacy of rhIL-11[J].Oncology (Williston Park),2000,14(9 Suppl 8):32-40.

共引文献32

同被引文献24

  • 1崔旭,何生,刘霆,邓长安,孟文彤.脾切除术治疗难治性ITP60例临床疗效分析[J].四川大学学报(医学版),2005,36(3):447-448. 被引量:3
  • 2付惠玲,吴焕卿,徐靖华.特发性血小板减少性紫癜多中心治疗[J].医药论坛杂志,2005,26(10):30-31. 被引量:1
  • 3何志旭.特发性血小板减少性紫癜诊断治疗进展[J].实用儿科临床杂志,2007,22(15):1131-1134. 被引量:17
  • 4Buskard N, Rock G, Nair R. The Canadian experience using plasma exchange fir immune thrombocytopenic purpura. Canadian Apheresis Group [J]. Transfus Sci, 1998,19 ( 3 ) :295 - 300.
  • 5Cahill MR, Macey MG, Cavenagh JD, et al. Protein A immunoad-sorption in chronic refractory ITP reverses increased platelet activa- tion but fails to achieve sustained clinical benefit[ J]. Br J Haema- to1,1998,100(2) :358 -364.
  • 6黄璩 王鉴 吴倩倩.急性特发性血小板减少性紫癜两种疗法近期疗效观察.实用医学杂志,2001,:52-52.
  • 7Katkhouda N, Manhas S, Umbach TW, et al. Laparoscopic splenecto- my [ J ]. J Laparoendosc Adv Surg Tech A, 2001,11 ( 6 ) : 383 - 390.
  • 8Scaradavou A, Bussel JB. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura[ J~. Semin Hema- to1,1998,35( 1 suppl 1 ) :52 -57.
  • 9Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with idiopathic thrombocyt openic purpura[ J). Blood,2001,98(4) :952 -957.
  • 10Nishimura S, Ishida T, Imai K, et al. Monoclonal antibody therapy for disorders of hemostasis and coagulation [ J]. Nippon Rinsho, 2002, 60(3) :525 -530.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部